Zurich-Schlieren, March 16, 2018.  Molecular Partners AG (ticker: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, today published its audited Financial Results for 2017 and the company’s 2017 Annual Report.

Zurich-Schlieren, March 06, 2018.  Molecular Partners AG (ticker: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, today announced that it will present at the Cowen and Company 38th Annual Healthcare Conference on Tuesday, March 13, 2018

Zurich-Schlieren, February 19, 2018.  Molecular Partners AG (ticker: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, today announced that Allergan has exercised the third option to develop and commercialize DARPin® product candidates

Research & Development: MP0250 in multiple myeloma (MM): Promising initial safety and efficacy data from the ongoing phase 2 study of MP0250 MP0250 in EGFR-mutated non-small cell lung cancer (EGFR mut NSCLC): Following FDA approval of IND for phase 1b/2 study on track to dose first patient in Q1

Zurich-Schlieren, January 08, 2018.  Molecular Partners AG (ticker: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, today announced initial safety and efficacy data from its ongoing phase 2 study of MP0250 in multiple myeloma (MM).

Zurich-Schlieren, January 04, 2018.  Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced that it will present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, 10 January, 2018 at

Zurich-Schlieren, January 03, 2018.  Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies,today announced that Allergan has exercised two options to develop and commercialize DARPin® product candidates from its 2012

Company begins development of MP0310, first DARPin® therapy in early-stage immuno-oncology portfolio R&D Update and webcast today highlights continued progress in pipeline in oncology and ophthalmology Zurich-Schlieren, November 09, 2017.  Molecular Partners AG (SIX: MOLN), a clinical-stage

Zurich-Schlieren, October 31, 2017.  At today’s Extraordinary General Meeting of Molecular Partners (SIX: MOLN), the shareholders of the company approved the election of William (Bill) Burns, former CEO of Roche Pharmaceuticals, and Patrick Amstutz, CEO of Molecular Partners, as new members of the

Research & Development highlights: MP0250:  Phase 2 study in Multiple Myeloma progressing well and according to plan MP0250:  FDA accepted the company’s IND (submitted in August 2017) for phase 2 study evaluating MP0250 in EGFR-mutated Non-Small Cell Lung Cancer (EGFR mut NSCLC); on track to dose